Precision Therapeutics

About Precision Therapeutics

Precision Therapeutics, often associated with Genomenon, provides a suite of genomic services and a cutting-edge software platform called Mastermind to inform and accelerate drug development. The company leverages artificial intelligence to analyze and interpret vast genomic datasets, offering detailed insights at both the gene and variant levels. Its services are designed for the precision medicine sector, tailoring treatments to individuals based on their genetic profile.

The company's offerings are structured around providing expertly curated, real-world evidence from published genomic research. This includes Custom Genomic Services, which help partners understand the genetic landscape of a disease to support the entire drug development lifecycle. Specific services include Variant Evidence, to design evidence-based inclusion criteria for clinical trials, and Patient Evidence, which provides real-world data from published cases. Precision Therapeutics also develops custom genetic knowledge bases for applications like target identification, risk factor analysis, and prevalence estimation. Their Mastermind Genomic Intelligence Platform is a key product, using AI to provide insights that connect cancer variants to therapies and clinical trials.

The business operates by partnering with pharmaceutical and biotech companies to empower their decision-making with genomic data, aiming to save time and resources. The core of their business model is to provide a more effective, personalized approach to treatment by focusing on the underlying genetic causes of diseases like cancer, thereby reducing side effects compared to conventional therapies. This approach helps in identifying therapeutic targets and defining patient subgroups, which is critical in precision medicine.